GlassScriptPhysician profile
Shashi Kumar
NPI 1710949466
$231,136.87
in general payments reported to CMS, 2019-2025
38 companies · $846 in 2025
The $846 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $20K · 2021: $22K · 2022: $48K · 2023: $24K · 2024: $57K · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Travel and Lodging: $7,000 · Food and Beverage: $6,053 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,245.00 |
| Travel and Lodging | $6,999.71 |
| Food and Beverage | $6,052.61 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $102,986.15 | 2019-2025 | Epclusa, Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $39,489.47 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $38,759.21 | 2024-2025 | Voquezna |
| Abbvie INC. | $19,390.09 | 2019-2025 | |
| Pfizer INC. | $7,405.88 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,528.57 | 2019-2021 | |
| Celgene Corporation | $5,344.70 | 2021-2024 | Zeposia |
| Dova Pharmaceuticals | $2,834.32 | 2019 | |
| Aries Pharmaceuticals, INC. | $2,318.94 | 2019 | |
| Allergan, INC. | $2,018.78 | 2019 | |
| Boston Scientific Corporation | $1,684.33 | 2019-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Cre Pro |
| Ardelyx, INC. | $1,621.67 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $212.74 | 2019-2024 | |
| Braintree Laboratories, INC. | $195.54 | 2020-2025 | Sutab, Suflave |
| Abbott Laboratories | $175.50 | 2024 | Amplatzer Amulet, Octrode |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashi Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.